STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Key Inclusion criteria: * male or female patients of 18 years of age or older, scheduled or expected to receive at least two cycles of chemotherapy over at least a two- month period as primary or adjuvant therapy for any malignancy, * have experienced NCI Common Toxicity Grade 1 - 4 diarrhea during previous chemotherapy treatment or are currently experiencing Grade 1-4 diarrhea due to chemotherapy treatment Key Exclusion criteria: * females who are pregnant or lactating, * current use of anticoagulants, except for those who are receiving 1 mg/per day of Coumadin for port maintenance, * known hypersensitivity to Sandostatin, Sandostatin LAR ® Depot or other related drug or compound, * history or presence of Crohn™s disease, ulcerative colitis, sprue, or known C. difficile infection, or any other diarrheal syndrome, * WBC \< 3000 /L, Platelets \< 75,000 /L, serum creatinine \>2.0 mg/dL